Prochlorperazine is recommended for adults with breakthrough or refractory chemotherapy-induced nausea and vomiting (CINV). The objective of this review was to describe its safety in children when given for any indication to help define its role for CINV control in children.
Electronic searches of MEDLINE, EMBASE, PsycINFO, and the Cochrane Central Register of Controlled Trials were performed as of 9 March 2015. All studies in English reporting adverse effects (AEs) associated with prochlorperazine in children (≤18 years) were included. AEs were synthesized for prospective studies.
Forty-nine (15 prospective) studies evaluating the use of prochlorperazine in 758 children were included. The most commonly reported AEs in prospective studies of prochlorperazine in children were sedation (multiple-dose studies: 10 %, 95 % CI 5–21) and extrapyramidal symptoms (EPS) (single-dose studies: 9 %, 95 % CI 3–29; multiple-dose studies: 4 %, 95 % CI 1–11). Serious AEs (seizure, neuroleptic malignant syndrome, autonomic collapse, tardive dyskinesia) were rarely associated with prochlorperazine use in children. Five fatalities were reported in children receiving prochlorperazine.
The limitations of this systematic review and meta-analysis were that the AEs reported in the included studies were heterogeneous, the prospective use of systematic clinical tools to identify AEs was rare, and the risk of bias in most prospective studies was moderate.
The most common AEs reported with the pediatric use of prochlorperazine are EPS and sedation. Fatalities, life-threatening, and persistent AEs have also been reported.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
National Comprehensive Cancer Network. Antiemesis version 2. 2014. http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. Accessed 19 Jun 2014.
Hayden J, van der Windt D, Cartwright J, Cote P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158(4):280–6.
Brousseau DC, Duffy SJ, Anderson AC, Linakis JG. Treatment of pediatric migraine headaches: a randomized, double-blind trial of prochlorperazine versus ketorolac. Ann Emerg Med. 2004;43(2):256–62.
Chan HS, Correia JA, MacLeod SM. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics. 1987;79(6):946–52.
Illingworth RS, Harvey CC. Prevention of migraine in children by prochlorperazine. Lancet. 1960;1(7116):132.
Mitchell AC, Hargis C, McCarry F, Powers C. Effects of prochlorperazine therapy on educability in disturbed mentally retarded adolescents. Am J Ment Defic. 1959;64:57–62.
Schaaf M, Payne CA. Dystonic reactions to prochlorperazine in hypoparathyroidism. N Engl J Med. 1966;275(18):991–5.
Nahata MC, Ford C, Ruymann FB. Pharmacokinetics and safety of prochlorperazine in paediatric patients receiving cancer chemotherapy. J Clin Pharm Ther. 1992;17(2):121–3.
Trottier ED, Bailey B, Lucas N, Lortie A. Prochlorperazine in children with migraine: a look at its effectiveness and rate of akathisia. Am J Emerg Med. 2012;30(3):456–63.
Dougan HT. Prochlorperazine. Med Times. 1959;87(6):802–5.
Berman HH, Lazar M, Noe O. Prochlorperazine as an antiemetic in the severely retarded child. AMA J Dis Child. 1958;95(2):146–9.
Daeschner GL, Matthes FT, Daeschner CW Jr. Treatment of nausea and vomiting in children with prochlorperazine. J Pediatr. 1958;53(2):148–52.
Hopkins CE, Geppert TV. Vomiting in infancy and early childhood; treatment with prochlorperazine. J Pediatr. 1958;52(6):687–9.
Cytryn L, Gilbert A, Eisenberg L. The effectiveness of tranquilizing drugs plus supportive psychotherapy in treating behavior disorders of children: a double-blind study of eighty outpatients. Am J Orthopsychiatr. 1960;30(1):113–29.
Rosenblum S, Buoniconto P, Graham B. “Compazine” vs. placebo: A controlled study with educable, emotionally disturbed children. Am J Ment Defic. 1960;64:713–7.
Tuft HS. Prochlorperazlne as an aid in the treatment of bronchial asthma. Ann Allergy. 1959;17(21):224–9.
Paul AK. Pre anaesthetic medication in children with promethazine and prochlorperazine. Indian Med J. 1977;71(2):30–1.
Kabbouche MA, Vockell AL, LeCates SL, Powers SW, Hershey AD. Tolerability and effectiveness of prochlorperazine for intractable migraine in children. Pediatrics. 2001;107(4):E62.
Trottier ED, Bailey B, Dauphin-Pierre S, Gravel J. Clinical outcomes of children treated with intravenous prochlorperazine for migraine in a pediatric emergency department. J Emerg Med. 2010;39(2):166–73.
Sharma DB, Lahori UC. Acute phenothiazine intoxication in children. Indian Pediatr. 1975;12(8):725–9.
Lankamp DJ, Willemse J, Pikaar SA, van Heyst AN. Prochlorperazine in childhood: side-effects. Clin Neurol Neurosurg. 1977;80(4):264–71.
Khatri R, Hershey AD, Wong B. Prochlorperazine—treatment for acute confusional migraine. Headache. 2009;49(3):477–80.
Bejar JM. Compazine-induced dyskinesia in a 14-month-old boy. Clin Neuropharmacol. 1984;7(2):171–2.
Feldman V. Serious reactions to phenothiazines. J Pediatr. 1976;89(1):163–4.
Jones R, Thompson JA. Intravenous calcium treatment of refractory hypotension in Reye’s syndrome. Arch Neurol. 1984;41(7):786–7.
Moore A, O’Donohoe NV, Monaghan H. Neuroleptic malignant syndrome. Arch Dis Child. 1986;61(8):793–5.
Shaw A, Matthews EE. Postoperative neuroleptic malignant syndrome. Anaesthesia. 1995;50(3):246–7.
Shaw EB, Dermott RV, Lee R, Burbridge TN. Phenothiazine tranquilizers as a cause of severe seizures. Pediatrics. 1959;23(3):485–92.
Browning DH, Ferry PC. Tardive dyskinesia in a ten-year-old boy. An undesirable sequel of phenothiazine medication. Clin Pediatr (Phila). 1976;15(10):955–7.
Hamilton JV, Dyer GY. Compazine intoxication in children: report of five cases. J Am Osteopath Assoc. 1960;59:789–91.
Harries JR. Oculogyric crises due to phenothiazines. Br Med J. 1967;3(5559):241.
Jabbour JT, Scheffield JA, Montalvo JM. Severe neurological manifestations in four children receiving compazine (prochlorperazine). J Pediatr. 1958;53(2):153–9.
Cottom DG, Newman CG. Dystonic reactions to phenothiazine derivatives. Arch Dis Child. 1966;41(219):551–3.
Moussa MAA, El-Hait SAS, Al-Khars A. Dystonic reactions to metoclopramide and prochlorperazine in children. J Kuwait Med Assoc. 1984;18(2):75–9.
Cleveland WW, Smith GF. Complications following the use of prochlorperazine (compazine) as an antiemetic. AMA J Dis Child. 1958;96(3):284–7.
Reecer MV, Clinchot DM, Tipton DB. Drug-induced dystonia in a patient with C4 quadriplegia. Case report. Am J Phys Med Rehabil. 1993;72(2):97–8.
Berk BZ. Reaction to prochlorperazine? Lancet. 1969;1(7598):776.
Jacobziner H, Raybin HW. Accidental chemical poisonings. Intoxications due to tranquilizing drugs and plants. NY State J Med. 1962;62(19):3130–2.
Mercer JK. Accidental administration of Compazine. IMJ Ill Med J. 1964;126:47–8.
The assistance of Ms. Elizabeth Uleryk, Library Scientist, with the literature search and the administrative assistance of Ms. Sandra Cabral are gratefully acknowledged.
Support of the Pediatric Oncology Group of Ontario to conduct the study and to prepare the manuscript is acknowledged. The funder did not influence the interpretation of the results of this work.
Conflict of interest
Melissa Lau Moon Lin, Paula D. Robinson, Jacqueline Flank, Lillian Sung, and L. Lee Dupuis have no conflicts of interest that are directly relevant to the content of this study.
About this article
Cite this article
Lau Moon Lin, M., Robinson, P.D., Flank, J. et al. The Safety of Prochlorperazine in Children: A Systematic Review and Meta-Analysis. Drug Saf 39, 509–516 (2016). https://doi.org/10.1007/s40264-016-0398-9
- Electronic Supplementary Material
- Cerebral Palsy
- Tardive Dyskinesia
- Neuroleptic Malignant Syndrome